Clincosm LogoSign in Get a demo

Peripheral Choroidal Layer Response

Sponsor
University of Houston (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05132140
Collaborator
(none)
40
Enrollment
1
Arm
17.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The study aims to examine how the vascular layer of the eyeball (choroidal layer) responds when part of the visual field is exposed to specially generated visual stimulus. The study goal will be accomplished by producing specific blur visual stimulus at a particular visual field position and measure any consistent thickness change pattern in the choroidal layer.

We propose to test the hypothesis that regional changes in the choroidal thickness may be induced differently after short-term exposure to specific visual stimuli.

Condition or Disease Intervention/Treatment Phase
  • Device: adaptive optics system
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Peripheral Choroidal Response to Pure Defocus and Oriented Blur Conditions
Anticipated Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: normal healthy group

Adaptive optics system: this system controls the optical quality of the eye at the peripheral visual field temporarily.

Device: adaptive optics system
the system consists of a wavefront sensor and a deformable mirror that measure and correct (or modify) the eye's optical imperfections (aberrations).

Outcome Measures

Primary Outcome Measures

  1. choroidal thickness [up to 60 mins]

    A commercially available optical coherence tomography system will be used to measure changes in choroidal layer thickness before and after manipulating the peripheral optics.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
A person is eligible for inclusion in the study if he/she:

  • Is between the ages of 18 and 40 yrs old

  • Has normal best corrected visual acuity being 20/20 or better

  • Has spherical refractive error between +1.00D and -6.00D.

  • Is capable of fixating on the target.

  • Has no prior ocular surgery.

  • Has no ocular pathology except keratoconus.

  • Can tolerate dilating eye drops

Exclusion Criteria:
A person will be excluded from the study if he/she:

  • Does not fall within above mentioned age group.

  • Has chronic or systemic eye disease that would interfere with pupil dilation via eye drops.

  • Underwent ocular surgeries or history of ocular trauma

  • Has shallow anterior chamber angle and/or glaucoma.

  • Has clinically significant dry eye.

  • Has signs of any choroidal or retinal pathology, and abnormalities in the visual pathway

  • Has spherical refractive error that exceeds the limits outlined above.

  • Has binocular anomalies (e.g. convergence insufficiency, strabismus, pseudo-myopia, amblyopia).

  • Is an adult unable to consent

  • Is an individual who is not yet adult (infants, children, teenagers)

  • Is a pregnant woman

  • Is a prisoner

  • Is a student for whom you have direct access to/influence on grades

  • Is an economically and/or educationally disadvantaged person

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Houston

Investigators

  • Principal Investigator: Geunyoung Yoon, PhD, University of Houston

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Geunyoung Yoon, Professor, University of Houston
ClinicalTrials.gov Identifier:
NCT05132140
Other Study ID Numbers:
  • STUDY00003210
First Posted:
Nov 24, 2021
Last Update Posted:
Nov 30, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Myopia

Study Results

No Results Posted as of Nov 30, 2021